FDA OKs HeartWare Device for Patients Awaiting Transplant (HTWR)

FDA OKs HeartWare Device for Patients Awaiting Transplant

HeartWare (Nasdaq: HTWR ) has received approval from the Food and Drug Administration for its Ventricular Assist System, the company and the FDA announced Tuesday.

The product is a mechanical heart pump that attaches directly to the organ in order to stimulate blood flow in end-stage heart failure patients. Unlike rival products, HeartWare's pump does not require surgical breach of the abdomen in order to be implanted.

According to the Massachusetts-based company, its product is the leading ventricular assist pump implanted in patients in non-U.S. markets, having received EU approval in 2009 and Australian approval in 2011. More than 2,500 patients have received the system.

HeartWare shares jumped on the news, advancing nearly 10%, or $7.53, to close at $89.54 on the day the announcements were made.

More Expert Advice from The Motley Fool

The Motley Fool's chief investment officer has selected his No. 1 stock for the next year. Find out which stock in our brand-new free report: "The Motley Fool's Top Stock for 2013." I invite you to take a copy, free for a limited time. Just click here to access the report and find out the name of this under-the-radar company.

Jeff Fischer and team have demystified options. And they can rack up income like $1,030... $2,626... and $3,228 on a schedule you can set your watch by!
That's why we're glad to announce every single one of their closely guarded strategies is available to YOU during May and June – 100% FREE, no strings attached! Just enter your email address in the box below...

Comments from our Foolish Readers

Help us keep this a respectfully Foolish area! This is a place for our readers to discuss, debate, and learn more about the Foolish investing topic you read about above. Help us keep it clean and safe. If you believe a comment is abusive or otherwise violates our Fool's Rules, please report it via the Report this Comment icon found on every comment.